Finance

Lists
INO:NASDAQ
Inovio Pharmaceuticals Inc
၁.၄၂ US$
-၀.၇၀%
(-၀.၀၁၀၀) 1D
နို ၁၆, GMT-၅ ၁၃:၂၃:၅၃  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
၁.၄၂ US$
High
၁.၄၈ US$
Low
၁.၃၇ US$
Mkt. cap
၂၆.၆၀ ကုဋေ
Avg. vol.
၁.၉၃ ကုဋေ
Volume
၃.၃၉ သန်း
52-wk high
၂.၇၂ US$
52-wk low
၀.၅၇ US$
EPS
-၀.၈၀ US$
Beta
၁.၇၁
Shares outstanding
၁၈.၇၃ ကုဋေ
No. of employees
၁၁၂
Open
၁.၄၂ US$
High
၁.၄၈ US$
Low
၁.၃၇ US$
Mkt. cap
၂၆.၆၀ ကုဋေ
Avg. vol.
၁.၉၃ ကုဋေ
Volume
၃.၃၉ သန်း
52-wk high
၂.၇၂ US$
52-wk low
၀.၅၇ US$
EPS
-၀.၈၀ US$
Beta
၁.၇၁
Shares outstanding
၁၈.၇၃ ကုဋေ
No. of employees
၁၁၂
News stories
From web sources and news partners
ChartMill
ChartMill
·
ပြီးခဲ့သည့် ၄၈ မိနစ်
Today's S&P 500 Top Movers: Tyson Foods Leads Gainers, Lumentum Leads Decliners
marketscreener.com
marketscreener.com
·
ပြီးခဲ့သည့် ၅၃ မိနစ်
Nasdaq, S&P 500 fall over 1% in run-up to Nvidia results, Anthropic debut
Stocktwits
Stocktwits
·
ပြီးခဲ့သည့် ၅၄ မိနစ်
Morgan Stanley’s Mike Wilson Is Bullish On S&P 500 With A 15% Upside View For 2027
Traders Union
Traders Union
·
ပြီးခဲ့သည့် ၂ နာရီ
Peter Tuchman: S&P 500 loses over $800 billion in market cap
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees၁၁၂
Founded၁၉၉၉
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current ၁.၄၂ US$
၈.၀၀ US$ (+၄၆၃.၃၈%)
Average
၆.၃၃ US$ (+၃၄၅.၇၇%)
Lowest
၅.၀၀ US$ (+၂၅၂.၁၁%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
၅.၀၀ US$
+၂၅၂.၁%
11/12/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
၆.၀၀ US$
+၃၂၂.၅%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
၈.၀၀ US$
+၄၆၃.၄%
11/06/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
၁၃.၀၀ US$
+၈၁၅.၅%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
-
-
-
၂.၉၉ သိန်း
Cost of goods sold
၁.၀၃ ကုဋေ
၁.၄၁ ကုဋေ
၁.၀၈ ကုဋေ
-
Cost of revenue
၁.၀၃ ကုဋေ
၁.၄၁ ကုဋေ
၁.၀၈ ကုဋေ
-
Research and development expenses
-
-
-
၁.၀၆ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၇.၂၂ သန်း
၇.၈၈ သန်း
၇.၈၀ သန်း
၉.၂၁ သန်း
Operating expense
၇.၂၂ သန်း
၇.၈၈ သန်း
၇.၈၀ သန်း
၁.၉၈ ကုဋေ
Total operating expenses
၁.၇၅ ကုဋေ
၂.၁၉ ကုဋေ
၁.၈၆ ကုဋေ
၁.၉၈ ကုဋေ
Operating income
-၁.၇၅ ကုဋေ
-၂.၁၉ ကုဋေ
-၁.၈၆ ကုဋေ
-၁.၉၅ ကုဋေ
Other non operating income
၂.၁၂ ကုဋေ
၄.၁၄ သန်း
၁.၂၇ ကုဋေ
-၃.၀၂ ကုဋေ
EBT including unusual items
၃.၇၆ သန်း
-၁.၉၇ ကုဋေ
-၆.၀၁ သန်း
-၄.၉၂ ကုဋေ
EBT excluding unusual items
၃.၇၅ သန်း
-၁.၉၅ ကုဋေ
-၅.၅၃ သန်း
-၄.၉၃ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
၃.၇၆ သန်း
-၁.၉၇ ကုဋေ
-၆.၀၁ သန်း
-၄.၉၂ ကုဋေ
Net profit margin
-
-
-
-၁၆,၄၆၁.၉၀%
Earnings per share
-၀.၂၈
-၀.၃၁
-၀.၂၄
-၀.၂၃
Interest and investment income
၄.၄၉ သိန်း
၄.၄၀ သိန်း
၃.၆၄ သိန်း
၃.၅၆ သိန်း
Interest expense
-
-
-
-
Net interest expenses
၄.၄၉ သိန်း
၄.၄၀ သိန်း
၃.၆၄ သိန်း
၃.၅၆ သိန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၇၁ ကုဋေ
-၂.၁၆ ကုဋေ
-၁.၈၃ ကုဋေ
-၁.၉၂ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ